Prestige Consumer Healthcare Balances Setbacks With Growth Plan

Prestige Consumer Healthcare ((PBH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Prestige Consumer Healthcare’s latest earnings call struck a notably balanced tone, pairing solid cash generation and resilient margins with clear acknowledgment of near‑term execution setbacks. Management emphasized that supply chain issues and geopolitical disruptions are pressuring results now, yet argued the company is building a stronger platform for medium‑term growth and deleveraging.

Robust Free Cash Flow Underpins Financial Flexibility

Prestige generated $246.4 million in free cash flow in fiscal 2026, a roughly 1.3% increase despite lower sales. Management now targets at least $250 million in free cash flow for fiscal 2027 and projects cumulative cash flow approaching $900 million over the next three years, excluding contributions from pending acquisitions.

Capital Allocation Balances Buybacks, M&A, and Deleveraging

The company deployed more than $150 million toward share repurchases in fiscal 2026 while investing about $110 million in the Pillar5 acquisition to secure eye care manufacturing. With over $90 million of repurchase authorization still available, Prestige reiterated its priorities of reinvesting in brands, reducing debt, and pursuing targeted M&A.

Margins Hold Firm Despite Top-Line Pressure

Adjusted gross margin for fiscal 2026 came in at 55.6%, essentially flat versus last year’s 55.8% even as sales declined. Prestige also maintained a low‑30s EBITDA margin profile, underscoring disciplined cost control and pricing actions that offset some of the volume and mix headwinds.

Strategic Deals Expand Manufacturing and Brand Portfolio

Prestige closed the Pillar5 purchase in December, bringing eye care production in‑house to improve control over a key category. It also announced pending deals for Breathe Right, expected to add more than $125 million in revenue, and LaCorium, projected around $40 million in sales and neutral‑to‑slightly accretive earnings once integrated.

Digital Channels and Core Franchises Remain Resilient

E‑commerce penetration reached about 18% of sales with continued double‑digit consumption growth, highlighting the strength of the company’s online execution. Key franchises held up well, with Fleet retaining more than 50% market share, gastrointestinal brands growing, Summer’s Eve stabilizing, and Monistat defending share even as its category declined.

Initial Fiscal 2027 Outlook Signals Modest Recovery

For fiscal 2027, management guided revenue to $1.10–$1.12 billion, implying organic growth of about 1–3%. Adjusted EPS is expected between $4.42 and $4.51, with first‑quarter revenue around $250 million and EPS near $0.87, while gross margins are projected to remain roughly in line with fiscal 2026 levels.

Light Capex Supports Strong Cash Conversion

Prestige continues to benefit from a low capital expenditure model, planning to spend roughly $25 million in fiscal 2027 even after including Pillar5. With capex running at only about 1–3% of sales, the company preserves its strong free cash flow conversion and maintains flexibility for debt reduction or further investment.

Medium-Term Growth Anchored by M&A and International

Management outlined a path to a revenue CAGR approaching 10% through fiscal 2029, driven by acquisitions, eventual recovery in eye care, and expanded international distribution. The company also targets an EPS CAGR of at least 8% over that period, with its international business potentially growing to about 20% of total sales.

Clear Eyes Supply Issues Create Near-Term Drag

Extended maintenance downtime and delayed shipments at Pillar5 sharply constrained Clear Eyes production, significantly hurting sales in fiscal 2026. These disruptions were a primary driver of the year’s revenue decline and are expected to continue contributing to volatility into the first quarter of fiscal 2027.

Revenue Declines Mark a Tough Fiscal 2026

Fourth‑quarter revenue fell to $281.6 million, a drop of about 5% year over year, or 6.4% when excluding foreign exchange effects. For the full fiscal year, revenue declined approximately 4%, or 4.5% organically, underscoring how supply constraints and regional disruptions overshadowed otherwise stable brand performance.

Guidance Miss Tied to Supply and Shipping Shocks

The company fell about $12 million short of its fourth‑quarter revenue guidance, with roughly two‑thirds of the miss stemming from eye care supply problems. The remaining third was blamed on Middle East shipping disruptions, compounded by the lap of a prior‑year benefit from roughly $7 million in e‑commerce order timing.

Profitability Impacted as Sales and Mix Weaken

Adjusted EPS slipped to $4.38 from $4.52 in the prior year, a decline of about $0.14 as lower volumes and gross margin pressure outweighed cost savings. In the fourth quarter, both adjusted EBITDA and EPS were down by high single digits, reflecting the combined effect of softer sales and unfavorable mix.

Geopolitical Tensions Weigh on International Business

Conflict in the Middle East disrupted distributor shipments, lengthened lead times, and delayed orders in key markets. As a result, international OTC sales declined 2.8% on a constant‑currency basis in fiscal 2026, and management cautioned that these headwinds will continue to pressure first‑quarter performance.

Operational Volatility Expected as Pillar5 Ramps

Management warned investors of period‑to‑period volatility as the newly acquired Pillar5 facility scales production and resolves bottlenecks. The company expects supply timing to curb growth in the first half of fiscal 2027, with most Clear Eyes production improvements weighted toward the back half of the year.

Higher G&A and New Debt Add Near-Term Pressure

Adjusted G&A expenses are expected to rise to about 10.5% of sales in fiscal 2027, driven by the inclusion of Pillar5 and normalized incentive compensation. The Breathe Right and LaCorium deals will be financed with new term loan debt, pushing leverage higher in the near term before Prestige focuses on deleveraging using its strong cash flow.

Conservative Guidance Reflects Uncertain Environment

Fiscal 2027 guidance implies only modest organic growth and largely flat gross margins, signaling management’s caution around supply reliability and consumer demand. The wider guidance range versus prior years underscores the operational and macro uncertainty, even as the company invests for a stronger growth profile beyond the next few quarters.

Guidance and Medium-Term Outlook

Prestige’s fiscal 2027 plan calls for $1.10–$1.12 billion in revenue, adjusted EPS of $4.42–$4.51, flat gross margins, advertising above 13% of sales, and free cash flow of at least $250 million. Over the next three years, management expects cumulative cash flow of roughly $900 million, leverage trending toward about 3x after the pending deals, and a path to near‑10% revenue and 8%‑plus EPS CAGR through fiscal 2029.

Prestige Consumer Healthcare’s call painted a picture of a company weathering real but temporary disruptions while preserving its financial strength and margin profile. For investors, the near term may remain choppy, yet the combination of strong cash generation, strategic acquisitions, and accelerating international and e‑commerce channels underpins a constructive longer‑term story.